YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Innate Pharma S.A. press release [https://seekingalpha.com/pr/20234909-innate-pharma-reports-first-half-2025-business-update-and-financial-results] (OTCPK:IPHYF [https://seekingalpha.com/symbol/IPHYF]): 1H GAAP EPS of -€0.25. * Revenue o…
Partner Sanofi advances SAR’514 / IPH6401, a trifunctional anti-BCMA NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, to first-in-human clinical trial in relapsed/refractory Multiple Myeloma…
MARSEILLE, France, July 07, 2023--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AM…
Phase 2 MATISSE trial is evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi (durvalumab) and chemotherapy in early stage lung cancer IPH5201 is developed in collaboration with AstraZeneca MARSEILLE,…
Phase 2 MATISSE trial is evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi (durvalumab) and chemotherapy in early stage lung cancer IPH5201 is developed in collaboration with AstraZeneca MARSEILLE,…
Efficacy results presented at the 17th International Conference on Malignant Lymphoma, have been analysed according to updated lymph node involvement classification and confirm clinical activity and favorable safety profile of lacutamab in…
Efficacy results of lacutamab in Mycosis Fungoides according to updated lymph node classification in the TELLOMAK Phase 2 study in advanced cutaneous T cell lymphomas MARSEILLE, France, June 12, 2023--(BUSINESS WIRE)--Innate Pharma SA (Eur…
IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET® platform, targeting CD20 developed for the treatment of B-cell non-Hodgkin's lymphomas IPH6501 is progressing towards a Phas…
Shares of Innate Pharma SA IPHA jumped 10.3% after partner Sanofi SNY announced that the FDA granted Fast Track Designation to pipeline candidate SAR’579 / IPH6101 for the treatment of hematological malignancies. This designation from the…
Shares of Innate Pharma (NASDAQ: IPHA) were up 8% Thursday morning after rising as much as 10.6% earlier in the day after the company said the Food and Drug Administration (FDA) had granted Fast Track Designation to a cancer therapy the co…
SAR’579, ANKET® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi. MARSEILLE, France, June 08, 2023--…
SAR’579, ANKET® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi. MARSEILLE, France, June 08, 2023--…
MARSEILLE, France, June 07, 2023--(BUSINESS WIRE)--Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regul…
SAR’579/IPH6101, ANKET® platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by partner Sanofi Preliminary data published…
MARSEILLE, France, May 23, 2023--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its senior management team are scheduled to participate in…
IPH6501, a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic developed for the treatment of B-cell non-Hodgkin's lymphomas, selected for oral presentation MARSEILLE, France, May 15, 2023--(BUSINESS WIRE)-…
MARSEILLE, France, May 12, 2023--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), whi…
Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies; Innate to receive $5m upfront payment and eligible to up to $410m in future milestonesplus roy…
MARSEILLE, France, May 09, 2023--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF…
Oral presentation on SAR’579 / IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123; SAR’579 / IPH6101 is ANKET® platform lead asset and under development by partner Sanofi Two Trial in Progress posters incl…
MARSEILLE, France, May 03, 2023--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Wednesday, May 10, 2023 at 2 p.m. CEST / 8…
MARSEILLE, France, April 26, 2023--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that it has filed a prospectus supplement with the Securities and Exchange Commission ("SE…
MARSEILLE, France, April 21, 2023--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its senior management team are scheduled to participate in the following u…
MARSEILLE, France, April 18, 2023--(BUSINESS WIRE)--Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regu…
The Annual General Meeting will be broadcasted live by the Company MARSEILLE, France, April 07, 2023--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") will hold its Annual G…
MARSEILLE, France, April 06, 2023--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the filing of its 2022 Universal Registration Document (Document d’enregistrement universe…
Takeda to obtain exclusive worldwide rights to develop, manufacture and commercialize Antibody Drug Conjugates (ADC) using a panel of selected antibodies developed by Innate MARSEILLE, France, April 03, 2023--(BUSINESS WIRE)--Regulatory Ne…
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2022 Earnings Call Transcript March 23, 2023 Operator: Ladies and gentlemen, thank you for standing by. My name is Brent and I will be your conference operator today. At this time, I would like to welcom…
Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET® program and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase 2 efficacy data for lacutamab in advanced cutane…
MARSEILLE, France, March 20, 2023--(BUSINESS WIRE)--Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regu…
MARSEILLE, France, March 16, 2023--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, March 23, 2023…
Innate Pharma does not have any financial exposure to Silicon Valley Bank MARSEILLE, France, March 13, 2023--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") has learned tha…
MARSEILLE, France, February 21, 2023--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or…
MARSEILLE, France, February 07, 2023--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its senior management team are scheduled to participate in the followin…
Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between Sanofi and Innate is now effective. MARSEILLE, France, January 25, 2023--(BUSINESS WIR…
Data show control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123 These results support clinical development of CD123-NKCE; A Phase 1/2 clinical trial by Sanofi is ongoing MARSEILLE, France, January…